Endocrine ophthalmopathy and radioiodine therapy.
Endocrine ophthalmopathy is to some degree present in most patients with Graves' disease. In few cases, a severe form of the condition develops and in the majority of these cases, the course of the eye problems has been influenced by the treatment for thyrotoxicosis. In this regard, radioiodine therapy has been increasingly recognized as carrying a special risk. Here, the current understanding of endocrine ophthalmopathy and the risks associated with the development of severe eye disease are discussed. The results of a retrospective investigation of patients with severe eye disease in our hospital, and the experience with corticosteroid administration following radioiodine in order to reduce the risk of ophthalmopathy, are also presented.
Karlsson
F Anders
FA
Section of Endocrinology and Diabetes, Institute of Medical Sciences, Uppsala University Hospital, Uppsala, S-751 85, Uppsala, Sweden. anders.karlsson@medsci.uu.se
D001323:Autoantibodies / Q000378:metabolism; D005938:Glucocorticoids / Q000627:therapeutic use; D006111:Graves Disease / Q000532:radiotherapy*; D049970:Graves Ophthalmopathy / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D011989:Receptors, Thyrotropin / Q000378:metabolism; D012189:Retrospective Studies
D001323:Autoantibodies; D005938:Glucocorticoids; D018828:Immunoglobulins, Thyroid-Stimulating; D007457:Iodine Radioisotopes; D011989:Receptors, Thyrotropin; C094372:thyrotropin-binding inhibitory immunoglobulin